Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Fear of cancer recurrence |
The primary outcome is the score of the validated 4-item Concerns About Recurrence Questionnaire (CARQ-4). A higher score indicates a higher level of FCR. A score of 12 or above is considered clinically relevant fear of cancer recurrence. |
The primary outcome will be evaluated at approx. 6-8 months after randomization. |
|
Primary |
Fear of cancer recurrence |
The primary outcome is the score of the validated 4-item Concerns About Recurrence Questionnaire (CARQ-4). A higher score indicates a higher level of FCR. A score of 12 or above is considered clinically relevant fear of cancer recurrence. |
The primary outcome will be evaluated at approx. 12 months follow-up |
|
Primary |
Fear of cancer recurrence |
The primary outcome is the score of the validated 4-item Concerns About Recurrence Questionnaire (CARQ-4). A higher score indicates a higher level of FCR. A score of 12 or above is considered clinically relevant fear of cancer recurrence. |
The primary outcome will be evaluated at approx. 24 months follow-up |
|
Secondary |
Evaluation of change from baseline in depression score by the validated Patient Health Questionnaire-9 (PhQ-9) |
The PhQ-9 has a scale from 0-27, and a higher score is associated with increase in depression severity |
Depression score will be evaluated at approx. 6-8 months after randomization. |
|
Secondary |
Evaluation of change from baseline in depression score by the validated Patient Health Questionnaire-9 (PhQ-9) |
The PhQ-9 has a scale from 0-27, and a higher score is associated with increase in depression severity |
Depression score will be evaluated at approx. 12 months follow-up |
|
Secondary |
Evaluation of change from in depression score by the validated Patient Health Questionnaire-9 (PhQ-9) |
The PhQ-9 has a scale from 0-27, and a higher score is associated with increase in depression severity |
Depression score will be evaluated at 24 months follow-up |
|
Secondary |
Evaluation of change from baseline in anxiety score by the validated General Anxiety Disorder-7 questionnaire (GAD-7) |
The GAD-7 has a scale from 0-21, and a higher score is associated with increase in anxiety severity. |
Anxiety score will be evaluated at approx. 6-8 months after randomization. |
|
Secondary |
Evaluation of change from baseline in anxiety score by the validated General Anxiety Disorder-7 questionnaire (GAD-7) |
The GAD-7 has a scale from 0-21, and a higher score is associated with increase in anxiety severity. |
Anxiety score will be evaluated at approx.12 months follow-up |
|
Secondary |
Evaluation of change from baseline in anxiety score by the validated General Anxiety Disorder-7 questionnaire (GAD-7) |
The GAD-7 has a scale from 0-21, and a higher score is associated with increase in anxiety severity. |
Anxiety score will be evaluated at approx. 24 months follow-up |
|
Secondary |
Evaluation of change from baseline in distress score by the validated distress thermometer |
The distress thermometer has a scale from 0-10, and a higher score is associated with increase in distress severity |
Distress score will be evaluated at approx. 6-8 months after randomization. |
|
Secondary |
Evaluation of change from baseline in distress score by the validated distress thermometer |
The distress thermometer has a scale from 0-10, and a higher score is associated with increase in distress severity |
Distress score will be evaluated at approx.12 months follow-up |
|
Secondary |
Evaluation of change from baseline in distress score by the validated distress thermometer |
The distress thermometer has a scale from 0-10, and a higher score is associated with increase in distress severity |
Distress score will be evaluated at approx. 24 months follow-up |
|
Secondary |
Evaluation of change from baseline in activation score by the validated patient activation measure |
The patient activation measure has a 100-point scale, and a higher score is associated with increase in activation level |
Activation measure will be evaluated at approx. 6-8 months after randomization. |
|
Secondary |
Evaluation of change from baseline in activation score by the validated patient activation measure |
The patient activation measure has a 100-point scale, and a higher score is associated with increase in activation level |
Activation measure will be evaluated at approx.12 months follow-up |
|
Secondary |
Evaluation of change from baseline in activation score by the validated patient activation measure |
The patient activation measure has a 100-point scale, and a higher score is associated with increase in activation level |
Activation measure will be evaluated at approx. 24 months follow-up |
|
Secondary |
Evaluation of change from baseline in health status by the validated Euroqol 5 dimensions, 3 levels questionnaire (EQ-5D-3L) |
The EQ-5D-3L has a 3-level scale, and a higher level is associated with decrease in health status |
Health status will be evaluated at approx. 6-8 months after randomization. |
|
Secondary |
Evaluation of change from baseline in health status by the validated Euroqol 5 dimensions, 3 levels questionnaire (EQ-5D-3L) |
The EQ-5D-3L has a 3-level scale, and a higher level is associated with decrease in health status |
Health status will be evaluated at approx.12 months follow-up |
|
Secondary |
Evaluation of change from baseline in health status by the validated Euroqol 5 dimensions, 3 levels questionnaire (EQ-5D-3L) |
The EQ-5D-3L has a 3-level scale, and a higher level is associated with decrease in health status |
Health status will be evaluated at approx. 24 months follow-up |
|
Secondary |
Evaluation of change from baseline in work ability by the validated work ability index |
The work ability index has a scale from 7-49, where higher scores indicates better work ability. |
Work ability will be evaluated at approx. 6-8 months after randomization. |
|
Secondary |
Evaluation of change from baseline in work ability by the validated work ability index |
The work ability index has a scale from 7-49, where higher scores indicates better work ability. |
Work ability will be evaluated at approx.12 months follow-up |
|
Secondary |
Evaluation of change from baseline in work ability by the validated work ability index |
The work ability index has a scale from 7-49, where higher scores indicates better work ability. |
Work ability will be evaluated at approx. 24 months follow-up |
|
Secondary |
Evaluation of the time and costs spend by the patients getting to and from the follow-up visits |
The patients will fill in a study specific questionnaire informing time and money spent for transportation to and from the follow-up visits |
Time and costs spend will be evaluated at approx. 6-8 months after randomization. |
|
Secondary |
Evaluation of the time and costs spend by the patients getting to and from the follow-up visits |
The patients will fill in a study specific questionnaire informing time and money spent for transportation to and from the follow-up visits |
Time and costs spend will be evaluated at approx.12 months follow-up |
|
Secondary |
Evaluation of the time and costs spend by the patients getting to and from the follow-up visits |
The patients will fill in a study specific questionnaire informing time and money spent for transportation to and from the follow-up visits |
Time and costs spend will be evaluated at approx. 24 months follow-up |
|
Secondary |
Evaluation of the number of extra clinical consultations with a doctor at the outpatient clinic |
The investigators will evaluate number of extra clinical consultations with a doctor the patients will attend at the outpatient clinic. The data will be collected using electronic patient journal. |
the number of extra clinical consultations with a doctor will be evaluated at approx. 6-8 months after randomization. |
|
Secondary |
Evaluation of the number of extra clinical consultations with a doctor at the outpatient clinic |
The investigators will evaluate number of extra clinical consultations with a doctor the patients will attend at the outpatient clinic. The data will be collected using electronic patient journal. |
the number of extra clinical consultations with a doctor will be evaluated at approx. 12 months follow-up |
|
Secondary |
Evaluation of the number of extra clinical consultations with a doctor at the outpatient clinic |
The investigators will evaluate number of extra clinical consultations with a doctor the patients will attend at the outpatient clinic. The data will be collected using electronic patient journal. |
the number of extra clinical consultations with a doctor will be evaluated at approx. 24 months follow-up |
|
Secondary |
Evaluation of the number of extra clinical consultations with a doctor at the outpatient clinic |
The investigators will evaluate number of extra clinical consultations with a doctor the patients will attend at the outpatient clinic. The data will be collected using electronic patient journal. |
the number of extra clinical consultations with a doctor will be evaluated at approx. 60 months follow-up |
|
Secondary |
Evaluation of the number and characteristics of new primary melanomas and/or recurrences |
The investigator will register any new melanomas and recurrences detected, and deaths. The data will be collected using medical records. |
Number and characteristics of new primary melanoma and/or recurrences will be evaluated at approx. 6-8 months after randomization. |
|
Secondary |
Evaluation of the number and characteristics of new primary melanomas and/or recurrences |
The investigator will register any new melanomas and recurrences detected, and deaths. The data will be collected using medical records. |
Number and characteristics of new primary melanoma and/or recurrences will be evaluated at approx.12 months follow-up |
|
Secondary |
Evaluation of the number and characteristics of new primary melanomas and/or recurrences |
The investigators will register any new melanomas and recurrences detected, and deaths. The data will be collected using medical records. |
Number and characteristics of new primary melanoma and/or recurrences will be evaluated at approx. 24 months follow-up |
|
Secondary |
Evaluation of the number and characteristics of new primary melanomas and/or recurrences |
The investigators will register any new melanomas and recurrences detected, and deaths. The data will be collected using medical records. |
Number and characteristics of new primary melanoma and/or recurrences will be evaluated at approx. 60 months follow-up |
|
Secondary |
Evaluation of time to diagnosis of a new primary melanoma and/or recurrence |
The investigators will evaluate time to diagnosis of a new melanomas using Breslows thickness as a proxy for time, and time to diagnosis recurrence measured by type of recurrence (local, regional or distant). The data will be collected using medical records. |
Time to diagnosis of a new primary melanoma and/or recurrence will be evaluated at approx. 6-8 months after randomization. |
|
Secondary |
Evaluation of time to diagnosis of a new primary melanoma and/or recurrence |
The investigators will evaluate time to diagnosis of a new melanomas using Breslows thickness as a proxy for time, and time to diagnosis recurrence measured by type of recurrence (local, regional or distant). The data will be collected using medical records. |
Time to diagnosis of a new primary melanoma and/or recurrence will be evaluated at approx. 12 months follow-up |
|
Secondary |
Evaluation of time to diagnosis of a new primary melanoma and/or recurrence |
The investigators will evaluate time to diagnosis of a new melanomas using Breslows thickness as a proxy for time, and time to diagnosis recurrence measured by type of recurrence (local, regional or distant). The data will be collected using medical records. |
Time to diagnosis of a new primary melanoma and/or recurrence will be evaluated at approx. 24 months follow-up |
|
Secondary |
Evaluation of time to diagnosis of a new primary melanoma and/or recurrence |
The investigators will evaluate time to diagnosis of a new melanomas using Breslows thickness as a proxy for time, and time to diagnosis recurrence measured by type of recurrence (local, regional or distant). The data will be collected using medical records. |
Time to diagnosis of a new primary melanoma and/or recurrence will be evaluated at approx. 60 months follow-up |
|
Secondary |
Evaluation of health care costs of the new follow-up program compared to the current |
We will evaluate the health care cost of new follow-up program compared to the current. Data will be collected using national registries. |
Health care costs evaluation will be evaluated at approx. 60 months follow-up |
|
Secondary |
Evaluation of the number of extra scans: Magnetic Resonance Imaging (MRI), computed tomography (CT), ultrasound, or positron emission tomography/computed tomography (PET/CT) |
The investigators will evaluate number of extra scans. The data will be collected using electronic patient journal. |
the number of extra scans will be evaluated at approx. 6-8 months after randomization. |
|
Secondary |
Evaluation of the number of extra scans: Magnetic Resonance Imaging (MRI), computed tomography (CT), ultrasound, or positron emission tomography/computed tomography (PET/CT) |
The investigators will evaluate number of extra scans. The data will be collected using electronic patient journal. |
the number of extra scans will be evaluated at approx. 12 months follow-up |
|
Secondary |
Evaluation of the number of extra scans: Magnetic Resonance Imaging (MRI), computed tomography (CT), ultrasound, or positron emission tomography/computed tomography (PET/CT) |
The investigators will evaluate number of extra scans. The data will be collected using electronic patient journal. |
the number of extra scans will be evaluated at approx. 24 months follow-up |
|
Secondary |
Evaluation of the number of extra scans: Magnetic Resonance Imaging (MRI), computed tomography (CT), ultrasound, or positron emission tomography/computed tomography (PET/CT) |
The investigators will evaluate number of extra scans. The data will be collected using electronic patient journal. |
the number of extra scans will be evaluated at approx. 60 months follow-up |
|